Careers Contact Us Facebook Twitter LinkedIn Home About Science Clinical Trials Patients & Families Investors & Media Investor Relations Abeona Therapeutics is a clinical-stage biopharmaceutical company focused on developing and delivering gene therapy products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. VIEW PRESENTATION OVERVIEW NEWS / EVENTS COMPANY INFO FINANCIAL INFO STOCK DATA SEC FILINGS GOVERNANCE INVESTOR TOOLS Latest News Nov 18, 2021 Abeona Therapeutics Announces Support of EB Research Partnership's Venture Into Cures Event to Raise Awareness for Education and Research of Epidermolysis Bullosa VIEW PRESS RELEASE Nov 17, 2021 Abeona Therapeutics Announces Presentation on Pivotal Transpher A Study of ABO-102 in MPS IIIA at the 14th ICIEM Conference VIEW PRESS RELEASE Nov 16, 2021 Abeona Therapeutics Announces Participation at the Jefferies London Healthcare Conference VIEW PRESS RELEASE VIEW ALL Latest Presentation Dec 2, 2021 Corporate Presentation VIEW PRESENTATION Latest Event Nov 23, 2021 • 11:45am - 1:15pm AEDT 14th ICIEM Conference VIEW ALL Fact Sheet Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. Our expertise across R&D, manufacture, and discovery of novel gene and cell therapies has us uniquely positioned to bring new medicines to patients in need. FACT SHEET Company Profile Abeona Therapeutics is focused on developing and delivering gene therapy products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Epidermolysis Bullosa, Sanfilippo syndrome, Batten disease, and other rare disorders. VIEW PROFILE VIEW MANAGEMENT TEAM VIEW CONTACTS Stock Information VIEW QUOTE VIEW CHARTS VIEW HISTORICAL DATA LATEST QUARTERLY RESULTS Q3 2021 Quarter Ended Sep 30, 2021 PDF HTML Earnings Release AUDIO Earnings Webcast PDF HTML 10-Q Filing ZIP XLS HTML XBRL VIEW ALL SEC FILINGS VIEW ALL FINANCIALS Governance at a Glance Chair Member BOARD MEMBERS AUDIT COMPENSATION NOMINATING AND CORPORATE GOVERNANCE Michael Amoroso Vishwas Seshadri, Ph.D., M.B.A. Christine Silverstein Todd Wider, M.D. Paul Mann Faith L. Charles Mark Alvino Leila Alland, M.D. Donald Wuchterl VIEW BOARD OF DIRECTORS VIEW BOARD COMMITTEES VIEW GOVERNANCE DOCUMENTS © 2021 Abeona Therapeutics Inc. All Rights Reserved. | Privacy Policy Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.